ISSN: 2228-5881 eISSN: 2251-7308

Adv Pharm Bull. 2016;6(3): 319-335. doi: 10.15171/apb.2016.044

PMID: 27766216 PMCID: PMC5071795

Review Article

Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective

Shringika Soni ¹, Rakesh Kumar Ruhela ¹, Bikash Medhi ¹ *

Cited by CrossRef: 79

1- Siafaka P, Okur N, Karantas I, Okur M, Gündoğdu E. Current update on nanoplatforms as therapeutic and diagnostic tools: A review for the materials used as nanotheranostics and imaging modalities. Asian Journal of Pharmaceutical Sciences. 2021;16(1):24 [Crossref]

2- Mutingwende F, Kondiah P, Ubanako P, Marimuthu T, Choonara Y. Advances in Nano-Enabled Platforms for the Treatment of Depression. Polymers. 2021;13(9):1431 [Crossref]

3- Mohapatra P, Gopikrishnan M, Doss C G, Chandrasekaran N. How Precise are Nanomedicines in Overcoming the Blood–Brain Barrier? A Comprehensive Review of the Literature. IJN. 2024;Volume 19:2441 [Crossref]

4- Tian M, Ma W, Chen Y, Yu Y, Zhu D, Shi J, Zhang Y. Impact of gender on the survival of patients with glioblastoma. 2018;38(6) [Crossref]

5- Zhang Y, Zou Z, Liu S, Miao S, Liu H. Nanogels as Novel Nanocarrier Systems for Efficient Delivery of CNS Therapeutics. Front Bioeng Biotechnol. 2022;10 [Crossref]

6- Mukherjee S, Madamsetty V, Bhattacharya D, Roy Chowdhury S, Paul M, Mukherjee A. Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics. Adv Funct Materials. 2020;30(35) [Crossref]

7- Garcia-Chica J, D Paraiso W, Tanabe S, Serra D, Herrero L, Casals N, Garcia J, Ariza X, Quader S, Rodriguez-Rodriguez R. An Overview of Nanomedicines for Neuron Targeting. Nanomedicine (Lond). 2020;15(16):1617 [Crossref]

8- Bonferoni M, Rossi S, Sandri G, Ferrari F. Nanoparticle formulations to enhance tumor targeting of poorly soluble polyphenols with potential anticancer properties. Seminars in Cancer Biology. 2017;46:205 [Crossref]

9- Rahman M, Islam F, Afsana Mim S, Khan M, Islam M, Haque M, Mitra S, Emran T, Rauf A, Sharma R. [Retracted] Multifunctional Therapeutic Approach of Nanomedicines against Inflammation in Cancer and Aging. Journal of Nanomaterials. 2022;2022(1) [Crossref]

10- Prasanth B, Alkhowaiter S, Sawarkar G, Dharshini B, R. Baskaran A. Unlocking Early Cancer Detection: Exploring Biomarkers, Circulating DNA, and Innovative Technological Approaches. 2023; [Crossref]

11- Łukasiewicz S, Błasiak E, Szczepanowicz K, Guzik K, Bzowska M, Warszyński P, Dziedzicka-Wasylewska M. The interaction of clozapine loaded nanocapsules with the hCMEC/D3 cells – In vitro model of blood brain barrier. Colloids and Surfaces B: Biointerfaces. 2017;159:200 [Crossref]

12- Wang J, Wang Q, Zhou F, Li J, Li Q, Zhou H, Li S, Ma S, Wen T. The antitumor effect of TAT-DCF1 peptide in glioma cells. Neuropeptides. 2018;71:21 [Crossref]

13- Mishra A, Ahsan R, Islam A, Tiwari R, Dash P. Hybrid Nanocarriers for Neurological Disorders: Diagnostic & Therapeutic Approach. NANOTEC. 2024;18(2):164 [Crossref]

14- Khedkar M, Sharma V, Anjum M, Singh S, Shah K, Alam P, Dewangan H. Paliperidone-loaded nose to brain targeted NLCS: optimisation, evaluation, histopathology and pharmacokinetic estimation for schizophernia. Journal of Microencapsulation. 2024;41(8):832 [Crossref]

15- Joseph S, M A A, Thomas S, Nair S. Nanomedicine as a future therapeutic approach for treating meningitis. Journal of Drug Delivery Science and Technology. 2022;67:102968 [Crossref]

16- Antonoglou O, Giannousi K, Mourdikoudis S, Dendrinou-Samara C. Magnetic nanoemulsions as candidates for Alzheimer’s disease dual imaging theranostics. Nanotechnology. 2020;31(46):465702 [Crossref]

17- Martano S, De Matteis V, Cascione M, Rinaldi R. Inorganic Nanomaterials versus Polymer-Based Nanoparticles for Overcoming Neurodegeneration. Nanomaterials. 2022;12(14):2337 [Crossref]

18- Ullah A, Lim S. Nanogels: Update on the methods of synthesis and applications for cardiovascular and neurological complications. Journal of Drug Delivery Science and Technology. 2022;77:103879 [Crossref]

19- Akhtar A, Andleeb A, Waris T, Bazzar M, Moradi A, Awan N, Yar M. Neurodegenerative diseases and effective drug delivery: A review of challenges and novel therapeutics. Journal of Controlled Release. 2021;330:1152 [Crossref]

20- Omar Khudhur Z, Karimian A, Asadi A, Abdolmaleki A. Hydrogel nanoparticles as new drug delivery system for CNS disorders. ChemistrySelect. 2024;9(8) [Crossref]

21- Verma R, Sartaj A, Qizilbash F, Ghoneim M, Alshehri S, Imam S, Kala C, Alam M, Gilani S, Taleuzzaman M. An Overview of the Neuropharmacological Potential of Thymoquinone and its Targeted Delivery Prospects for CNS Disorder. CDM. 2022;23(6):447 [Crossref]

22- Nair K, Ramaiyan V, Sukumaran S. Enhancement of drug permeability across blood brain barrier using nanoparticles in meningitis. Inflammopharmacol. 2018;26(3):675 [Crossref]

23- Mignani S, Shi X, Rodrigues J, Roy R, Muñoz-Fernández Á, Ceña V, Majoral J. Dendrimers toward Translational Nanotherapeutics: Concise Key Step Analysis. Bioconjugate Chem. 2020;31(9):2060 [Crossref]

24- Marino A, Tricinci O, Battaglini M, Filippeschi C, Mattoli V, Sinibaldi E, Ciofani G. A 3D Real‐Scale, Biomimetic, and Biohybrid Model of the Blood‐Brain Barrier Fabricated through Two‐Photon Lithography. Small. 2018;14(6) [Crossref]

25- Gonchar O, Maznychenko A, Klyuchko O, Mankovska I, Butowska K, Borowik A, Piosik J, Sokolowska I. C60 Fullerene Reduces 3-Nitropropionic Acid-Induced Oxidative Stress Disorders and Mitochondrial Dysfunction in Rats by Modulation of p53, Bcl-2 and Nrf2 Targeted Proteins. IJMS. 2021;22(11):5444 [Crossref]

26- Shala A, Arduino I, Salihu M, Denora N. Quercetin and Its Nano-Formulations for Brain Tumor Therapy—Current Developments and Future Perspectives for Paediatric Studies. Pharmaceutics. 2023;15(3):963 [Crossref]

27- Ross A, Mc Nulty D, O'Dwyer C, Grabrucker A, Cronin P, Mulvihill J. Standardization of research methods employed in assessing the interaction between metallic-based nanoparticles and the blood-brain barrier: Present and future perspectives. Journal of Controlled Release. 2019;296:202 [Crossref]

28- Vissers C, Ming G, Song H. Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders. Advanced Drug Delivery Reviews. 2019;148:239 [Crossref]

29- Pan F, Liu Y, Luo Z, Wang G, Li X, Liu H, Yu S, Qi D, Wang X, Chai X, Wang Q, Yin R, Pan Y. Discovering cholinesterase inhibitors from Chinese herbal medicine with deep learning models. Med Chem Res. 2024;33(7):1154 [Crossref]

30- Moura R, Pacheco C, Pêgo A, des Rieux A, Sarmento B. Lipid nanocapsules to enhance drug bioavailability to the central nervous system. Journal of Controlled Release. 2020;322:390 [Crossref]

31- German-Cortés J, Vilar-Hernández M, Rafael D, Abasolo I, Andrade F. Solid Lipid Nanoparticles: Multitasking Nano-Carriers for Cancer Treatment. Pharmaceutics. 2023;15(3):831 [Crossref]

32- Ghosh S, Basak P, Dutta S, Chowdhury S, Sil P. New insights into the ameliorative effects of ferulic acid in pathophysiological conditions. Food and Chemical Toxicology. 2017;103:41 [Crossref]

33- Collins M, Zamboni F, Serafin A, Escobar A, Stepanian R, Culebras M, Reis R, Oliveira J. Emerging scaffold- and cellular-based strategies for brain tissue regeneration and imaging. In vitro models. 2022;1(2):129 [Crossref]

34- Goswami P, Joshi N, Singh S. Neurodegenerative signaling factors and mechanisms in Parkinson's pathology. Toxicology in Vitro. 2017;43:104 [Crossref]

35- Saeedi M, Eslamifar M, Khezri K, Dizaj S. Applications of nanotechnology in drug delivery to the central nervous system. Biomedicine & Pharmacotherapy. 2019;111:666 [Crossref]

36- Vashist A, Kaushik A, Vashist A, Bala J, Nikkhah-Moshaie R, Sagar V, Nair M. Nanogels as potential drug nanocarriers for CNS drug delivery. Drug Discovery Today. 2018;23(7):1436 [Crossref]

37- Jan Z, Mollazadeh S, Abnous K, Taghdisi S, Danesh A, Ramezani M, Alibolandi M. Targeted Delivery Platforms for the Treatment of Multiple Sclerosis. Mol Pharmaceutics. 2022;19(7):1952 [Crossref]

38- Ikram M, Rasheed S. Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine: A Roadmap for Future Treatment of Drug Resistant Seizures. CMP. 2023;16(4):475 [Crossref]

39- Chen P, Dong B, Yao W. Numerical simulation study of nanoparticle diffusion in gray matter. Computational and Structural Biotechnology Journal. 2024;25:95 [Crossref]

40- Dhuri K, Vyas R, Blumenfeld L, Verma R, Bahal R. Nanoparticle Delivered Anti-miR-141-3p for Stroke Therapy. Cells. 2021;10(5):1011 [Crossref]

41- Zhao J, Koay E, Li T, Wen X, Li C. A hindsight reflection on the clinical studies of poly(l‐glutamic acid)‐paclitaxel. WIREs Nanomed Nanobiotechnol. 2018;10(3) [Crossref]

42- Bai X, Bian Z. MicroRNA-21 Is a Versatile Regulator and Potential Treatment Target in Central Nervous System Disorders. Front Mol Neurosci. 2022;15 [Crossref]

43- Ran W, Xue X. Theranostical application of nanomedicine for treating central nervous system disorders. Sci China Life Sci. 2018;61(4):392 [Crossref]

44- Liu T, Xie Q, Dong Z, Peng Q. Nanoparticles-based delivery system and its potentials in treating central nervous system disorders. Nanotechnology. 2022;33(45):452001 [Crossref]

45- Dhayalan M, Wang W, Riyaz S, Dinesh R, Shanmugam J, Irudayaraj S, Stalin A, Giri J, Mallik S, Hu R. Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications. 3 Biotech. 2024;14(2) [Crossref]

46- Rishitha N, Muthuraman A. Therapeutic evaluation of solid lipid nanoparticle of quercetin in pentylenetetrazole induced cognitive impairment of zebrafish. Life Sciences. 2018;199:80 [Crossref]

47- Lucena-Serrano C, Lucena-Serrano A, Díaz A, Valpuesta M, Villaverde G, Manuel López-Romero J, Sarabia F, Laurenti M, Rubio-Retama J, Contreras-Cáceres R. SPION nanoparticles for delivery of dopaminergic isoquinoline and benzazepine derivatives. Bioorganic & Medicinal Chemistry. 2022;69:116910 [Crossref]

48- Kumar J, Delgado S, Sarma H, Narayan M. Caffeic acid recarbonization: A green chemistry, sustainable carbon nano material platform to intervene in neurodegeneration induced by emerging contaminants. Environmental Research. 2023;237:116932 [Crossref]

49- Krsek A, Jagodic A, Baticic L. Nanomedicine in Neuroprotection, Neuroregeneration, and Blood–Brain Barrier Modulation: A Narrative Review. Medicina. 2024;60(9):1384 [Crossref]

50- Pinheiro R, Granja A, Loureiro J, Pereira M, Pinheiro M, Neves A, Reis S. RVG29-Functionalized Lipid Nanoparticles for Quercetin Brain Delivery and Alzheimer’s Disease. Pharm Res. 2020;37(7) [Crossref]

51- Rhaman M, Islam M, Akash S, Mim M, Noor alam M, Nepovimova E, Valis M, Kuca K, Sharma R. Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance. Front Cell Dev Biol. 2022;10 [Crossref]

52- Sharma R, Malviya R, Srivastava S, Ahmad I, Rab S, Uniyal P. Targeted Treatment Strategies for Mitochondria Dysfunction: Correlation with Neurological Disorders. CDT. 2024;25(10):683 [Crossref]

53- Maiuolo J, Carresi C, Gliozzi M, Mollace R, Scarano F, Scicchitano M, Macrì R, Nucera S, Bosco F, Oppedisano F, Ruga S, Coppoletta A, Guarnieri L, Cardamone A, Bava I, Musolino V, Paone S, Palma E, Mollace V. The Contribution of Gut Microbiota and Endothelial Dysfunction in the Development of Arterial Hypertension in Animal Models and in Humans. IJMS. 2022;23(7):3698 [Crossref]

54- Nordin N, Sadikan M, Lambuk L, Hashim S, Airuddin S, Mohd Nasir N, Mohamud R, Ibrahim J, Kadir R. Liposomal topical drug administration surpasses alternative methods in glaucoma therapeutics: a novel paradigm for enhanced treatment. 2024; [Crossref]

55- Teleanu D, Chircov C, Grumezescu A, Teleanu R. Neuronanomedicine: An Up-to-Date Overview. Pharmaceutics. 2019;11(3):101 [Crossref]

56- Kumar A, Tan A, Wong J, Spagnoli J, Lam J, Blevins B, G N, Thorne L, Ashkan K, Xie J, Liu H. Nanotechnology for Neuroscience: Promising Approaches for Diagnostics, Therapeutics and Brain Activity Mapping. Adv Funct Materials. 2017;27(39) [Crossref]